Recordati Reports Strong Financial Performance for 2025
Recordati has announced its impressive financial results for the first nine months of 2025, highlighting a consolidated net revenue of €1.956 billion. This marks a commendable increase of 12.2%, reflecting the company's robust market position.
Key Financial Highlights
One of the standout figures from the report is the EBITDA, which reached €743.9 million, displaying a growth of 11.8%. The margin on revenue for this period stood at an impressive 38%, underscoring sustainable profitability. Adjusted net income stood at €493.1 million, an increase of 10.7% compared to the previous year.
Revenue Breakdown
Recordati's growth in revenue is attributed to the strong performance across various segments. Their Specialty & Primary Care sector generated revenue of €1.130 billion, representing a growth of 3.2%. Meanwhile, the Rare Diseases segment saw remarkable growth of 29.2%, with revenue exceeding €782 million. This sector is particularly buoyed by the new treatment for Cushing's syndrome, Isturisa®, which has gained momentum in the market.
Investments in Growth and Development
Recognizing the potential within the Cushing's syndrome market, Recordati has increased its peak year sales target for Isturisa® to over €1.2 billion, doubling the previous estimate. This decision is rooted in the company's commitment to addressing the needs of the broader non-overt patient population. To facilitate this, Recordati plans to ramp up investments in commercial and medical activities by approximately €40-50 million annually.
Dividends and Shareholder Returns
In a move to reward shareholders, the Board of Directors has proposed an interim dividend of €0.63 per share, reinforcing the company's commitment to delivering value to its investors. This dividend will be payable to shareholders registered by November 24, 2025.
Market Outlook
Despite challenges posed by the macroeconomic landscape, including currency fluctuations, Recordati remains confident in achieving its fiscal 2025 targets. The company anticipates that rare diseases will approach 50% of total revenues by 2026, driven largely by the uptake of Isturisa® and other key growth assets. The outlook is optimistic, indicating potential for mid-single-digit growth in the Specialty & Primary Care segment as well.
Expansion into New Markets
In addition to strengthening its product offerings, Recordati is actively pursuing regulatory approvals and expanding its presence in international markets. The recent approval for Isturisa® in Canada and Russia opens new avenues for revenue growth and market penetration.
Future Developments
Looking ahead, Recordati is focused on continuing its investment in innovative treatments and expanding its product pipeline. The company is gearing up for several trials that could enhance its product line and address unmet medical needs in various segments.
Frequently Asked Questions
What are the key figures from Recordati’s Q3 2025 report?
Recordati's Q3 2025 report highlights a consolidated net revenue of €1.956 billion, with an EBITDA of €743.9 million and an adjusted net income of €493.1 million.
How much has the peak sales estimate for Isturisa® changed?
The peak sales estimate for Isturisa® has been raised from €550-650 million to over €1.2 billion.
What dividend has Recordati proposed for its shareholders?
Recordati has proposed an interim dividend of €0.63 per share, payable to shareholders registered by November 24, 2025.
What is the forecast for Rare Diseases revenue in 2026?
By 2026, Rare Diseases is expected to account for nearly 50% of Recordati's total revenues, driven by the growth of treatments like Isturisa®.
What initiatives is Recordati pursuing in the future?
Recordati is expanding its product pipeline and enhancing its market presence internationally while investing in clinical trials that address unmet medical needs.
